Advertisement
American Journal of Kidney Diseases

The Effect of Spironolactone on Acute Kidney Injury After Cardiac Surgery: A Randomized, Placebo-Controlled Trial

Published:August 10, 2016DOI:https://doi.org/10.1053/j.ajkd.2016.06.013

      Background

      Cardiac surgery−related acute kidney injury (AKI) is a common postoperative complication that greatly increases morbidity and mortality. There are currently no effective interventions to prevent AKI associated with cardiac surgery. Experimental data have shown that administration of the mineralocorticoid receptor blocker spironolactone prevents renal injury induced by ischemia-reperfusion in rats. The objective of this study was to test whether short-term perioperative administration of oral spironolactone could reduce the incidence of AKI in cardiac surgical patients.

      Study Design

      Randomized, double-blinded, placebo-controlled trial.

      Setting & Participants

      Data were collected from April 2014 through July 2015 at the National Heart Institute in Mexico. 233 patients were included; 115 and 118 received spironolactone or placebo, respectively.

      Intervention

      Spironolactone or placebo once at a dose of 100 mg 12 to 24 hours before surgery and subsequently 3 further doses of 25 mg in postoperative days 0, 1, and 2 were administered.

      Outcomes

      Patients were followed up for 7 days or until discharge from the intensive care unit (ICU). The primary end point was AKI incidence defined by KDIGO criteria. Secondary end points included requirement of renal replacement therapy, ICU length of stay, and ICU mortality. Data were analyzed according to the intention-to-treat principle.

      Results

      Mean age was 53.2 ± 15 years, mean serum creatinine level was 0.9 ± 0.2 mg/dL, median Thakar score for estimation of AKI risk was 2 (IQR, 1-3), and 25% had diabetes. The incidence of AKI was higher for the spironolactone group (43% vs 29%; P = 0.02). No significant differences were found for secondary end points.

      Limitations

      Single center, AKI was mostly driven by AKI stage 1, planned sample size was not achieved, and there was no renin-angiotensin-aldosterone system washout period.

      Conclusions

      Our trial demonstrated that spironolactone was not protective for AKI associated with cardiac surgery and there may be a trend toward risk.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mehta R.
        • Grab J.
        • O'Brien S.
        • et al.
        Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery.
        Circulation. 2006; 114: 2208-2216
        • Rosner M.H.
        • Okusa M.D.
        Acute kidney injury associated with cardiac surgery.
        Clin J Am Soc Nephrol. 2006; 1: 19-32
        • Thakar C.V.
        • Worley S.
        • Arrigain S.
        • Yared J.P.
        • Paganini E.P.
        Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function.
        Kidney Int. 2005; 67: 1112-1119
        • Mangano C.M.
        • Diamondstone L.S.
        • Ramsay J.G.
        • Aggarwal A.
        • Herskowitz A.
        • Mangano D.T.
        • The Multicenter Study of Perioperative Ischemia Research Group
        Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization.
        Ann Intern Med. 1998; 128: 194-203
        • Ryckwaert F.
        • Boccara G.
        • Frappier J.M.
        • Colson P.H.
        Incidence, risk factors, and prognosis of a moderate increase in plasma creatinine early after cardiac surgery.
        Crit Care Med. 2002; 30: 1495-1498
        • Abel R.M.
        • Buckley M.J.
        • Austen W.G.
        • Barnett G.O.
        • Beck Jr., C.H.
        • Fischer J.E.
        Etiology, incidence, and prognosis of renal failure following cardiac operations: results of a prospective analysis of 500 consecutive patients.
        J Thorac Cardiovasc Surg. 1976; 71: 323-333
        • Bhat J.G.
        • Gluck M.C.
        • Lowenstein J.
        • Baldwin D.S.
        Renal failure after open heart surgery.
        Ann Intern Med. 1976; 84: 677-682
        • Coppolino G.
        • Presta P.
        • Saturno L.
        • Fuiano G.
        Acute kidney injury in patients undergoing cardiac surgery.
        J Nephrol. 2013; 26: 32-40
        • Coca S.G.
        • Yusuf B.
        • Shilpak M.G.
        • Garg A.X.
        • Parikh C.R.
        Long term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis.
        Am J Kidney Dis. 2009; 53: 961-973
        • Chawla L.S.
        • Amdur R.L.
        • Amodeo S.
        • Kimmel P.L.
        • Palant C.E.
        The severity of acute kidney injury predicts progression to chronic kidney disease.
        Kidney Int. 2011; 79: 1361-1369
        • Tang A.T.
        • El-Gamel A.
        • Keevil B.
        • Yonan N.
        • Deiraniya A.K.
        The effect of ‘renal-dose’ dopamine on renal tubular function following cardiac surgery: assessed by measuring retinol binding protein (RBP).
        Eur J Cardiothorac Surg. 1999; 15: 717-721
        • Lassnigg A.
        • Donner E.
        • Grubhofer G.
        • Presterl E.
        • Druml W.
        • Hiesmayr M.
        Lack of renoprotective effects of dopamine and furosemide during cardiac surgery.
        J Am Soc Nephrol. 2000; 11: 97-104
        • Lombardi R.
        • Ferreiro A.
        • Servetto C.
        Renal function after cardiac surgery: adverse effect of furosemide.
        Ren Fail. 2003; 25: 775-786
        • Ranucci M.
        • Soro G.
        • Barzaghi N.
        • et al.
        Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients.
        Ann Thorac Surg. 2004; 78: 1332-1337
        • Kramer B.K.
        • Preuner J.
        • Ebenburger A.
        • et al.
        Lack of renoprotective effect of theophylline during aortocoronary bypass surgery.
        Nephrol Dial Transplant. 2002; 17: 910-915
        • Carcoana O.V.
        • Mathew J.P.
        • Davis E.
        • et al.
        Mannitol and dopamine in patients undergoing cardiopulmonary bypass: a randomized clinical trial.
        Anesth Analg. 2003; 97: 1222-1229
        • Sward K.
        • Valsson F.
        • Odencrants P.
        • Samuelsson O.
        • Ricksten S.E.
        Recombinant human atrial natriuretic peptide in ischemic acute renal failure. A randomized placebo controlled trial.
        Crit Care Med. 2004; 32: 1310-1315
        • Boldt J.
        • Brosch C.
        • Piper S.N.
        • Suttner S.
        • Lehmann A.
        • Werling C.
        Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients.
        Crit Care Med. 2001; 29: 952-958
        • Prowle J.R.
        • Calzavacca P.
        • Licari E.
        • et al.
        Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery.
        Nephrology (Carlton). 2012; 17: 215-224
        • Bonventre J.V.
        • Weinberg J.M.
        Recent advances in the pathophysiology of isquemic acute renal failure.
        J Am Soc Nephrol. 2003; 14: 2199-2210
        • Arima S.
        • Kohagura K.
        • Xu H.L.
        • et al.
        Nongenomic vascular action of aldosterone in the glomerular microcirculation.
        J Am Soc Nephrol. 2003; 14: 2255-2263
        • Leopold J.A.
        • Dam A.
        • Maron B.A.
        • et al.
        Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.
        Nat Med. 2007; 13: 189-197
        • Mejia-Vilet J.M.
        • Ramirez V.
        • Cruz C.
        • Uribe N.
        • Gamba G.
        • Bobadilla N.A.
        Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone.
        Am J Physiol Renal Physiol. 2007; 293: F78-F86
        • Sanchez-Pozos K.
        • Barrera-Chimal J.
        • Garzón-Muvdi J.
        • et al.
        Recovery from ischemic acute kidney injury by spironolactone administration.
        Nephrol Dial Transplant. 2012; 27: 3160-3169
        • Moguel-González B.
        • Wasung-de-Lay M.
        • Tella-Vega P.
        • et al.
        Acute kidney injury in cardiac surgery.
        Rev Invest Clin. 2013; 65: 467-475
        • Thakar C.V.
        • Arrigain S.
        • Worley S.
        • Yared J.P.
        • Paganini E.P.
        A clinical score to predict acute renal failure after cardiac surgery.
        J Am Soc Nephrol. 2005; 16: 162-168
        • Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group
        KDIGO clinical practice guideline for acute kidney injury.
        Kidney Int Suppl. 2012; 2: 1-138
        • Ramirez V.
        • Trujillo J.
        • Valdes R.
        • et al.
        Adrenalectomy prevents renal ischemia-reperfusion injury.
        Am J Physiol Renal Physiol. 2009; 297: F932-F942
        • Barrera Chimal J.
        • Pérez-Villalva R.
        • Rodríguez-Romo R.
        • et al.
        Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury.
        Kidney Int. 2013; 83: 93-103
        • Barrera-Chimal J.
        • Prince S.
        • Fadel F.
        • et al.
        Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia.
        J Am Soc Nephrol. 2016; 27: 398-404
        • Dorrance A.M.
        • Osborn H.L.
        • Grekin R.
        • Webb R.C.
        Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats.
        Am J Physiol Regul Integr Comp Physiol. 2001; 281: R944-R950
        • Chai W.
        • Garrelds I.M.
        • Arulmani U.
        • Schoemaker R.G.
        • Lamers J.M.
        • Danser A.H.
        Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?.
        Br J Pharmacol. 2005; 145: 664-671
        • Pretorius M.
        • Murray K.T.
        • Yu C.
        • et al.
        Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
        Crit Care Med. 2012; 40: 2805-2812
        • Cremer J.
        • Martin M.
        • Redl H.
        • et al.
        Systemic inflammatory response syndrome after cardiac operations.
        Ann Thorac Surg. 1996; 61: 1714-1720
        • Sheridan A.M.
        • Bonventre J.V.
        Cell biology and molecular mechanisms of injury in ischemic acute renal failure.
        Curr Opin Nephrol Hypertens. 2000; 9: 427-434
        • Sreeram G.M.
        • Grocott H.P.
        • White W.D.
        • Newman M.F.
        • Stafford-Smith M.
        Transcranial Doppler emboli count predicts rise in creatinine after coronary artery bypass graft surgery.
        J Cardiothorac Vasc Anesth. 2004; 18: 548-551
        • Blauth C.I.
        Macroemboli and microemboli during cardiopulmonary bypass.
        Ann Thorac Surg. 1995; 59: 1300-1303
        • Parekh D.J.
        • Weinberg J.M.
        • Ercole B.
        • et al.
        Tolerance of the human kidney to isolated controlled ischemia.
        J Am Soc Nephrol. 2013; 24: 506-517
        • Yamamoto T.
        • Noiri E.
        • Ono Y.
        • et al.
        Renal L-type fatty acid–binding protein in acute ischemic injury.
        J Am Soc Nephrol. 2007; 18: 2894-2902
        • The RALES Investigators
        Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]).
        Am J Cardiol. 1996; 78: 902-907
        • Lee N.V.
        • Miller P.W.
        • Buono M.J.
        The effect of spironolactone on sweat and urinary sodium excretion during exercise in humans.
        Clin Physiol Funct Imaging. 2010; 30: 13-16
        • Skali H.1
        • Uno H.
        • Levey A.S.
        • Inker L.A.
        • Pfeffer M.A.
        • Solomon S.D.
        Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation.
        Am Heart J. 2011; 162: 548-554